Advances of Systemic Treatment for Adult Soft-Tissue Sarcoma

Wenshuai Liu; Quan Jiang; Yuhong Zhou


Chin Clin Oncol. 2018;7(4) 

In This Article


Soft-tissue sarcomas (STS) are a group of rare but highly heterogeneous neoplasms with mesenchymal origin. The curative management for localized disease is surgical resection, combined with or without radiotherapy (RT) for selected patients. Systemic treatment with cytotoxic chemotherapy and molecular targeted agents is one of the main therapeutic modalities in patients with advanced or metastatic disease. While adjuvant and neoadjuvant chemotherapy for pediatric sarcoma such as rhabdomyosarcomas, Ewing sarcomas and osteosarcomas is established, it's role in adult-type sarcomas remains controversial. With the increasing knowledge in the molecular basis of pathogenesis of sarcoma and emerging of novel drugs, the treatment outcomes for patients with STS will improve greatly in the future. In this review, we aim to summarize the advances of chemotherapy, targeted therapy and immunotherapy in the management of STS.